Edition:
United Kingdom

Gensight Biologics SA (SIGHT.PA)

SIGHT.PA on Paris Stock Exchange

1.78EUR
19 Oct 2018
Change (% chg)

€-0.09 (-4.80%)
Prev Close
€1.88
Open
€1.89
Day's High
€1.92
Day's Low
€1.75
Volume
343,636
Avg. Vol
60,840
52-wk High
€7.68
52-wk Low
€1.68

Latest Key Developments (Source: Significant Developments)

Gensight Biologics H1 Net Loss Widens To 11.7 Million Euros
Wednesday, 25 Jul 2018 

July 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS INTERIM FINANCIAL RESULTS FOR THE FIRST HALF OF 2018.H1 NET LOSS EUR 11.7 MILLION VERSUS LOSS OF EUR 10.1 MILLION YEAR AGO.OPERATING INCOME REMAINED STABLE OVER PERIOD, AMOUNTING TO EUR 2.0 MILLION IN H1 OF 2017 AND 2018.  Full Article

Gensight Biologics Reports Positive Results From Phase I/Ii Study Of Gs010
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS POSITIVE LONG-TERM VISUAL ACUITY GAINS AND SAFETY RESULTS FROM PHASE I/II STUDY OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON).CONFIRMATION OF THE FAVORABLE LONG-TERM SAFETY PROFILE OF GS010‍​.SIGNIFICANT IMPROVEMENT OF VISUAL ACUITY AT 2.5 YEARS OF FOLLOW-UP IN CERTAIN LHON PATIENTS.LHON PATIENTS WITH LESS THAN 2 YEARS OF ONSET OF VISUAL LOSS PRIOR TO TREATMENT.  Full Article

Gensight Biologics: cash and cash equivalents position at Sept 30 at EUR 59.5​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - GENSIGHT BIOLOGICS SA : :‍CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 59.5 MILLION AS OF SEPTEMBER 30, 2017, COMPARED TO EUR 63.6 MILLION AS OF JUNE 30, 2017.​.  Full Article

Gensight Biologics appoints Barrett Katz as Chief Medical Officer
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS APPOINTS BARRETT KATZ AS CHIEF MEDICAL OFFICER.  Full Article

BRIEF-Gensight Biologics cash position slightly dips, issues update on GS010

* GenSight Biologics’ cash and cash equivalents amounted to €49.2 million as of March 31, 2018, compared to €55.4 million as of December 31, 2017